Myokardia Inc., of South San Francisco, priced an underwritten public offering of 4.93 million shares of its common stock at $51 per share, the proceeds from which it will use to fund trials, preclinical programs, R&D and corporate needs, it said. Oppenheimer & Co. acted as the sole book-running manager. Myokardia shares (NASDAQ:MYOK) fell by $1.10 cents, or 2.1 percent, to $51 on Wednesday.